Chemosensitivity Testing in Melanoma
Author Information
Author(s): K.M. Tveit, S. Gundersen, J. Hoie, A. Pihl
Primary Institution: The Norwegian Radium Hospital and Institute for Cancer Research
Hypothesis
Can an in vitro chemosensitivity assay predict the response of malignant melanoma patients to chemotherapy?
Conclusion
The chemosensitivity assay is reliable but the current chemotherapy agents for melanoma are too ineffective to justify routine use of the assay.
Supporting Evidence
- 100% sensitivity and 87-98% specificity were observed in the chemosensitivity assay.
- The response rate was low, with only a few patients showing any positive response to treatment.
- The median survival time was not significantly different between the two treatment series.
Takeaway
Doctors tested a method to see if it could predict which melanoma patients would respond to chemotherapy, but the drugs didn't work well enough to make the test useful.
Methodology
A retrospective and prospective trial using an in vitro chemosensitivity assay based on the Courtenay and Mills soft agar cultivation method.
Limitations
A low percentage of evaluable tests due to insufficient cell numbers or inadequate growth.
Participant Demographics
Patients with malignant melanomas, including metastases or local recurrences.
Statistical Information
P-Value
0.09
Statistical Significance
p=0.09
Want to read the original?
Access the complete publication on the publisher's website